不同的塞马鲁肽方案导致急性胰腺炎：最新荟萃分析

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM Endocrinologia Diabetes Y Nutricion Pub Date : 2024-03-01 DOI:10.1016/j.endien.2024.03.012

Walter Masson , Martín Lobo , Leandro Barbagelata , Augusto Lavalle-Cobo , Juan P. Nogueira

{"title":"不同的塞马鲁肽方案导致急性胰腺炎：最新荟萃分析","authors":"Walter Masson , Martín Lobo , Leandro Barbagelata , Augusto Lavalle-Cobo , Juan P. Nogueira","doi":"10.1016/j.endien.2024.03.012","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Some concerns persist regarding the safety of semaglutide. The objective of this updated meta-analysis is to assess the risk of acute pancreatitis with the use of semaglutide, assessing the results according to the different administration regimens.</p></div><div><h3>Methods</h3><p>We performed an updated meta-analysis of randomised, placebo-controlled studies of semaglutide therapy that report acute pancreatitis. This meta-analysis was performed in line with PRISMA guidelines. A global and stratified analysis according to the therapeutic scheme used was performed using the fixed-effects model.</p></div><div><h3>Results</h3><p>Twenty-one eligible trials of semaglutide, including 34,721 patients, were identified and considered eligible for the analyses. Globally, semaglutide therapy was not associated with an increased risk of acute pancreatitis (OR 0.7; 95% CI 0.5–1.2, <em>I</em><sup>2</sup> 0%). When we analysed the studies according to the different schemes used, the results were similar (group with oral semaglutide: OR 0.40; 95% CI 0.10–1.60, <em>I</em><sup>2</sup> 0%; group with low subcutaneous doses of semaglutide: OR 0.80; 95% CI 0.40–1.90, <em>I</em><sup>2</sup> 0%; group with high subcutaneous doses of semaglutide: OR 0.70; 95% CI 0.50–1.20, <em>I</em><sup>2</sup> 0%; interaction <em>p</em>-value=0.689).</p></div><div><h3>Conclusion</h3><p>This updated meta-analysis demonstrates that the use of semaglutide is not associated with an increased risk of acute pancreatitis compared to placebo. In the stratified analysis, the results were similar with the different semaglutide regimens analysed.</p></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"71 3","pages":"Pages 124-132"},"PeriodicalIF":1.8000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis\",\"authors\":\"Walter Masson , Martín Lobo , Leandro Barbagelata , Augusto Lavalle-Cobo , Juan P. Nogueira\",\"doi\":\"10.1016/j.endien.2024.03.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>Some concerns persist regarding the safety of semaglutide. The objective of this updated meta-analysis is to assess the risk of acute pancreatitis with the use of semaglutide, assessing the results according to the different administration regimens.</p></div><div><h3>Methods</h3><p>We performed an updated meta-analysis of randomised, placebo-controlled studies of semaglutide therapy that report acute pancreatitis. This meta-analysis was performed in line with PRISMA guidelines. A global and stratified analysis according to the therapeutic scheme used was performed using the fixed-effects model.</p></div><div><h3>Results</h3><p>Twenty-one eligible trials of semaglutide, including 34,721 patients, were identified and considered eligible for the analyses. Globally, semaglutide therapy was not associated with an increased risk of acute pancreatitis (OR 0.7; 95% CI 0.5–1.2, <em>I</em><sup>2</sup> 0%). When we analysed the studies according to the different schemes used, the results were similar (group with oral semaglutide: OR 0.40; 95% CI 0.10–1.60, <em>I</em><sup>2</sup> 0%; group with low subcutaneous doses of semaglutide: OR 0.80; 95% CI 0.40–1.90, <em>I</em><sup>2</sup> 0%; group with high subcutaneous doses of semaglutide: OR 0.70; 95% CI 0.50–1.20, <em>I</em><sup>2</sup> 0%; interaction <em>p</em>-value=0.689).</p></div><div><h3>Conclusion</h3><p>This updated meta-analysis demonstrates that the use of semaglutide is not associated with an increased risk of acute pancreatitis compared to placebo. In the stratified analysis, the results were similar with the different semaglutide regimens analysed.</p></div>\",\"PeriodicalId\":48650,\"journal\":{\"name\":\"Endocrinologia Diabetes Y Nutricion\",\"volume\":\"71 3\",\"pages\":\"Pages 124-132\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrinologia Diabetes Y Nutricion\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2530018024000295\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinologia Diabetes Y Nutricion","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2530018024000295","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

目的人们对塞马鲁肽的安全性仍然存在一些担忧。本最新荟萃分析旨在评估使用塞马鲁肽引发急性胰腺炎的风险，并根据不同的给药方案对结果进行评估。方法我们对报告了急性胰腺炎的塞马鲁肽治疗随机安慰剂对照研究进行了最新荟萃分析。该荟萃分析符合 PRISMA 指南。结果确定了21项符合条件的塞马鲁肽试验，包括34721名患者，并认为这些试验符合分析条件。从总体上看，塞马鲁肽治疗与急性胰腺炎风险的增加无关（OR 0.7；95% CI 0.5-1.2，I2 0%）。当我们根据所使用的不同方案对研究进行分析时，结果相似（口服塞马鲁肽组，OR 0.40; 95% CI 0.5-1.2，I2 0%）：OR为0.40；95% CI为0.10-1.60，I2为0%；使用低剂量皮下注射塞马鲁肽的研究组：OR0.80；95% CI 0.40-1.90，I2 0%；皮下注射高剂量塞马鲁肽组：结论这项最新荟萃分析表明，与安慰剂相比，使用塞马鲁肽不会增加急性胰腺炎的风险。在分层分析中，所分析的不同塞马鲁肽治疗方案的结果相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis

Objectives

Some concerns persist regarding the safety of semaglutide. The objective of this updated meta-analysis is to assess the risk of acute pancreatitis with the use of semaglutide, assessing the results according to the different administration regimens.

Methods

We performed an updated meta-analysis of randomised, placebo-controlled studies of semaglutide therapy that report acute pancreatitis. This meta-analysis was performed in line with PRISMA guidelines. A global and stratified analysis according to the therapeutic scheme used was performed using the fixed-effects model.

Results

Twenty-one eligible trials of semaglutide, including 34,721 patients, were identified and considered eligible for the analyses. Globally, semaglutide therapy was not associated with an increased risk of acute pancreatitis (OR 0.7; 95% CI 0.5–1.2, I² 0%). When we analysed the studies according to the different schemes used, the results were similar (group with oral semaglutide: OR 0.40; 95% CI 0.10–1.60, I² 0%; group with low subcutaneous doses of semaglutide: OR 0.80; 95% CI 0.40–1.90, I² 0%; group with high subcutaneous doses of semaglutide: OR 0.70; 95% CI 0.50–1.20, I² 0%; interaction p-value = 0.689).

Conclusion

This updated meta-analysis demonstrates that the use of semaglutide is not associated with an increased risk of acute pancreatitis compared to placebo. In the stratified analysis, the results were similar with the different semaglutide regimens analysed.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Endocrinologia Diabetes Y Nutricion Multiple-

CiteScore

2.10

自引率

10.50%

发文量

期刊介绍： Endocrinología, Diabetes y Nutrición is the official journal of the Spanish Society of Endocrinology and Nutrition (Sociedad Española de Endocrinología y Nutrición, SEEN) and the Spanish Society of Diabetes (Sociedad Española de Diabetes, SED), and was founded in 1954. The aim of the journal is to improve knowledge and be a useful tool in practice for clinical and laboratory specialists, trainee physicians, researchers, and nurses interested in endocrinology, diabetes, nutrition and related disciplines. It is an international journal published in Spanish (print and online) and English (online), covering different fields of endocrinology and metabolism, including diabetes, obesity, and nutrition disorders, as well as the most relevant research produced mainly in Spanish language territories. The quality of the contents is ensured by a prestigious national and international board, and by a selected panel of specialists involved in a rigorous peer review. The result is that only manuscripts containing high quality research and with utmost interest for clinicians and professionals related in the field are published. The Journal publishes Original clinical and research articles, Reviews, Special articles, Clinical Guidelines, Position Statements from both societies and Letters to the editor. Endocrinología, Diabetes y Nutrición can be found at Science Citation Index Expanded, Medline/PubMed and SCOPUS.